Our objective was to assess, using clinical trial simulation, the feasibility of a fixed 200-µg dose of darbepoetin alfa (Aranesp) administered every 2 weeks in chemotherapy-induced anemia. A pharmacokinetic/pharmacodynamic
Bin Yao, MS
Advertisement
Articles by Bin Yao, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
2
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
3
FDA ODAC Votes Yes to Capivasertib for PTEN-Deficient Metastatic HSPC
4
Taletrectinib Demonstrates Durable Efficacy in ROS1-Positive NSCLC
5